Treatment of chronic fatigue syndrome and fibromyalgia syndrome
US7553829B2 · kind B2 · utility
0Cited by
15References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 31, 2001 |
| Grant date | Jun 30, 2009 |
| Priority date | — |
| Expiry date | Jan 4, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chronic fatigue syndrome (CFS) and fibromyalgia syndrome (FMS) can be treated by the administration of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.